Texas MPN Workshop 2022 | Combination approaches in MPNs: a promising option for JAK inhibitor-naive patients
In this video, Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights various combination approaches being explored in myeloproliferative neoplasms (MPNs) for the treatment of JAK inhibitor-naive patients, including pelabresib in combination with ruxolitinib, and navitoclax in combination with ruxolitinib. Dr Bose also shares some insights into the potential role of other agents, such as selinexor and luspatercept, and where these may fit in the treatment landscape. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research support: Incyte, BMS, CTI BioPharma, Kartos, Morphosys, Blueprint Medicines, Cogent, IONIS, Astellas, Pfizer, NS Pharma, Promedior.
Honoraria: Incyte, BMS, CTI BioPharma, Kartos, Morphosys, Blueprint Medicines, Cogent, Abbvie, Sierra Oncology (now GSK), Karyopharm, Pharma Essentia, Novartis.
